Get the Stockscreener App
1.04
0.00%
0.00
Context Therapeutics Inc stock is traded at $1.04, with a volume of 546.36K.
It is up +0.00% in the last 24 hours and down -11.86% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$1.04
Open:
$1.04
24h Volume:
546.36K
Relative Volume:
1.37
Market Cap:
$95.55M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-1.1429
EPS:
-0.91
Net Cash Flow:
$-31.63M
1W Performance:
-0.95%
1M Performance:
-11.86%
6M Performance:
+59.36%
1Y Performance:
-27.78%
1-Day Range:
$1.02
$1.06
1-Week Range:
$0.9949
$1.1285
52-Week Range:
$0.49
$1.55
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Compare CNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
1.04 | 95.55M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Guggenheim | Buy |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | JMP Securities | Mkt Outperform |
| Nov-25-24 | Initiated | D. Boral Capital | Buy |
| May-16-24 | Initiated | Piper Sandler | Overweight |
Context Therapeutics Inc Stock (CNTX) Latest News
Unpacking Q3 Earnings: CoStar (NASDAQ:CSGP) In The Context Of Other Data & Business Process Services Stocks - Yahoo Finance
Context Therapeutics Inc (CNTX) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - setenews.com
Context Therapeutics Names Dr. Karen Smith as Interim Chief Medical Officer - MSN
Is Context Therapeutics Inc. stock attractive for growth ETFs2025 Volume Leaders & AI Powered Trade Plan Recommendations - Newser
Unpacking Q3 Earnings: Axon (NASDAQ:AXON) In The Context Of Other Aerospace and Defense Stocks - Yahoo Finance
Why Context Therapeutics Inc. stock remains on buy listsMarket Growth Report & Momentum Based Trading Signals - BỘ NỘI VỤ
CT-202, a tumor-selective pH-dependent Nectin-4/CD3 TCE - BioWorld MedTech
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.40 Average Target Price from Brokerages - Defense World
Ag Growth International (AGGZF) Projected to Post Quarterly Earnings on Friday - Defense World
Context Therapeutics Inc. (NASDAQ:CNTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Context Therapeutics (NASDAQ:CNTX) Upgraded to “Sell” at Wall Street Zen - Defense World
Context Therapeutics (NASDAQ:CNTX) Upgraded to "Sell" at Wall Street Zen - MarketBeat
What drives Context Therapeutics Inc stock priceTrading Volume Trends & Affordable Growth Strategies - earlytimes.in
Jim Cramer Discusses Rockwell (ROK) Automation in the Context of Ongoing Industrial Revolution - Yahoo Finance
What technical charts say about Context Therapeutics Inc. stockWeekly Stock Analysis & Free Fast Gain Swing Trade Alerts - newser.com
Why analysts remain bullish on Context Therapeutics Inc. stockSwing Trade & Accurate Intraday Trading Signals - newser.com
Is Context Therapeutics Inc. stock a safe buy before earnings2025 Performance Recap & Technical Entry and Exit Alerts - newser.com
Is Context Therapeutics Inc. stock poised for growthJuly 2025 Decliners & Long-Term Growth Plans - newser.com
Unpacking Q3 Earnings: Amneal (NASDAQ:AMRX) In The Context Of Other Generic Pharmaceuticals Stocks - Yahoo Finance
Palvella Races Toward Key 2026 Readouts as Rare-Disease Pipeline Expands Rapidly - MyChesCo
Using portfolio simulators with Context Therapeutics Inc. includedMarket Growth Report & Long-Term Capital Growth Ideas - newser.com
Published on: 2025-11-16 17:23:15 - newser.com
Unpacking Q3 Earnings: Take-Two (NASDAQ:TTWO) In The Context Of Other Consumer Internet Stocks - Yahoo Finance
What’s the recovery path for long term holders of Context Therapeutics Inc.Market Risk Report & Daily Stock Momentum Reports - newser.com
Is Context Therapeutics Inc. stock resilient to inflationJuly 2025 Snapshot & Fast Moving Stock Watchlists - newser.com
Published on: 2025-11-15 13:42:26 - newser.com
Exit strategy if you’re trapped in Context Therapeutics Inc.July 2025 WrapUp & AI Enhanced Trading Alerts - newser.com
Is Context Therapeutics Inc. stock a top pick in earnings seasonJuly 2025 Trade Ideas & Smart Money Movement Alerts - newser.com
Is Context Therapeutics Inc. stock positioned well for digital economyGlobal Markets & Risk Controlled Daily Plans - newser.com
How institutional buying supports Context Therapeutics Inc. stockAnalyst Downgrade & Stepwise Trade Signal Guides - Fundação Cultural do Pará
Does Context Therapeutics Inc. stock trade at a discount to peers2025 Dividend Review & Verified Entry Point Detection - newser.com
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - The Manila Times
BioAtla, Inc. Q3 Earnings Call Highlights Progress and Challenges - TipRanks
Context Therapeutics Reports Encouraging Early Data in Cancer Trials, Eyes 2026 Milestones - MyChesCo
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Context Therapeutics Inc Stock (CNTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Levit Alex C. | Chief Legal Officer, Corp. Sec |
Jun 06 '25 |
Buy |
0.58 |
20,000 |
11,520 |
29,000 |
| Minai-Azary Jennifer Lynn | Chief Financial Officer |
Jun 06 '25 |
Buy |
0.64 |
40,010 |
25,486 |
80,010 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):